Trials that use: Wilcoxon / Mann-Whitney test
New to this method? Read the tutorial →
13 results
- ALIASIndependent statistical analysis of ALIAS, a randomized phase 3 trial of albumin versus saline in acute ischemic stroke, including trial design, endpoints, logistic regression, risk ratios, nonparametric analysis, safety, and interpretation.
- AMBITIONIndependent statistical analysis of the AMBITION phase 3 trial of first-line ambrisentan and tadalafil combination therapy in pulmonary arterial hypertension, including time-to-event analysis, secondary endpoints, statistical methodology, safety, and interpretation.
- ARTEMIS-IPFIndependent statistical analysis of ARTEMIS-IPF, the randomized phase 3 trial of ambrisentan versus placebo in idiopathic pulmonary fibrosis, including its time-to-event endpoint, hazard ratio, secondary analyses, statistical methods, and interpretation.
- CLEOPATRAIndependent statistical analysis of CLEOPATRA, the randomized phase 3 trial of pertuzumab plus trastuzumab and docetaxel versus placebo plus trastuzumab and docetaxel in previously untreated HER2-positive metastatic breast cancer.
- COMPASS-2Independent statistical analysis of COMPASS-2, evaluating bosentan added to sildenafil versus sildenafil monotherapy in pulmonary arterial hypertension, including time-to-event, functional, biomarker, quality-of-life, and safety results.
- FREEDOM-CIndependent statistical analysis of FREEDOM-C, evaluating oral treprostinil versus placebo in pulmonary arterial hypertension, including trial design, 6MWD results, secondary endpoints, post-hoc analyses, statistical methodology, and interpretation.
- FREEDOM-C2Independent statistical analysis of the FREEDOM-C2 phase 3 trial of UT-15C SR versus placebo for pulmonary arterial hypertension, including the 6-minute walk distance endpoint, non-parametric ANCOVA, secondary analyses, safety, and statistical interpretation.
- FREEDOM-MIndependent statistical analysis of FREEDOM-M, a randomized phase 3 trial of oral treprostinil versus placebo for pulmonary arterial hypertension, including 6-minute walk distance, statistical methodology, secondary analyses, safety, and interpretation.
- GS-US-292-0109Independent statistical analysis of GS-US-292-0109 (NCT01815736), a randomized phase 3 trial evaluating switching from a TDF-containing regimen to E/C/F/TAF in virologically suppressed HIV-1-positive participants.
- iPrExIndependent statistical analysis of the randomized phase 3 iPrEx trial of daily TDF/FTC versus placebo for HIV prevention in men, including primary efficacy and safety endpoints, secondary analyses, statistical methods, and interpretation.
- PATENT-1Independent statistical analysis of PATENT-1, a randomized phase 3 trial of oral riociguat in patients with pulmonary arterial hypertension, covering its 6-minute walking distance endpoint, ANCOVA, nonparametric and stratified analyses, secondary outcomes,…
- SINGLEComplete statistical analysis of the SINGLE phase 3 trial comparing dolutegravir plus abacavir/lamivudine with Atripla in HIV-1 infection, including the Week 48 primary endpoint, later virologic suppression analyses, CD4 outcomes, non-inferiority methodology,…
- STELLARIndependent statistical analysis of the phase 3 STELLAR trial of sotatercept plus background PAH therapy versus placebo plus background PAH therapy in pulmonary arterial hypertension, including trial design, endpoints, nonparametric analyses, hazard…